Brind.

AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.

Steady: 1 in the last 7 days Updated saturday

The latest in this situation

  1. Medicare coverage expansion boosts Parkinson's sales; newer therapies offset Humira's patent expiry.
  2. AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.
  3. AbbVie confirms successful transition away from Humira following patent loss.

How it started

5 reports, 4 independent, last reported Sat 00:00. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.

Who's involved

What this event is mainly about
AbbVieHUMIRAFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Medicare coverage expansion boosts Parkinson's sales; newer therapies offset Humira's patent expiry.1 source
  2. AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Sub-event
  3. AbbVie confirms successful transition away from Humira following patent loss.1 source
  4. AbbVie gained EEA approval for Boey and new products offset Humira declines.1 source
  5. AbbVie's market success and FDA approvals drive pipeline growth amid Fed caution.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped